Quigley Pharma Identifies Strains Including Influenza `A' New Caledonia, Influenza `A' Moscow and Influenza `B' Guangdong
DOYLESTOWN, Pa., Oct. 1 /PRNewswire-FirstCall/ -- The Quigley Corporation (NASDAQ: QGLY) today announced that a previously assigned Patent Application for an all-natural compound will also serve as the basis for what it expects to become a series of formulations effective in killing various virus strains of influenza. This latest in-vitro study was independently audited and confirmed to be found effective in killing Influenza `A' and Influenza `B', as specified above. The next step in the process to bring these potential product formulations to the market will be to conduct pre-clinical modeling studies.
In-vitro tests are conducted outside of the human body in a laboratory environment, as a precursor to pre-clinical modeling studies, leading finally to human trials.
This formulation has been extended beyond its previously announced application, which was found to be effective in killing the herpes virus in two in-vitro studies.
Consistent with the previously announced herpes in-vitro studies, the latest Quigley-sponsored in-vitro studies were conducted under the direction of world-renowned virologist Professor John Oxford, and may continue to be broadened to determine the compound's effectiveness against even further additional pathogens.
Dr. Oxford is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. He is the co-author of two standard texts on influenza and virology and has published 250 scientific papers throughout the world. Professor Oxford serves as the Scientific Director of Retroscreen, Ltd., the College's research virology company.
In a statement, Professor Oxford said that an independent audit of his previously conducted in-vitro study of the new Quigley Pharma formulation has been confirmed to be effective in killing three virulent strains against the current influenza `A' and `B' viruses. He further recommended that additional model studies be made, which, if successful, he would publish in a reputable medical journal. These would be followed by human clinical trials, the results of which, if successful, will also be published. Professor Oxford further confirmed that The Quigley Corporation had agreed to undertake the modeling study as soon as possible.
Dr. Richard Rosenbloom, Chief Operating Officer of Quigley Pharma, stated, "There is sufficient evidence in the in-vitro studies to proceed to the next level of clinical development in the approval process."
Guy J. Quigley, President, Chairman and Chief Executive Officer of The Quigley Corporation, stated, "We are continuing our ongoing research and development efforts at Quigley Pharma. Under the direction of Dr. Rosenbloom, our goal is to continue the expansion of its pipeline of potential new medications to bring to the market."
Interested registered shareholders who wish to review a copy of this report may contact Mr. Carl Fonash, shareholder relations at (267) 880-1111.
No claims are being made for the potential medicine discussed in this press release to be safe, effective, or approved by the Federal Food and Drug Administration (FDA).
The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar-free tablets. Cold-Eeze is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.quigleypharma.com/), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.